Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Fry

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Journal of Environmental Management|October 29, 2013
Evaluating Ireland's IBIA as an approach to improving the quality and effectiveness of biodiversity impact assessmentAinhoa González, Tamara Hochstrasser, John Fry, et al.
Journal of Human Kinetics|July 18, 2017
A Comparison of GPS Workload Demands in Match Play and Small-Sided Games by the Positional Role in Youth SoccerMathew Beenham, David J Barron, John Fry, et al.
Antiviral Therapy|November 21, 2025
A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participantsEd Gane, Christian Schwabe, Min Wu, et al.
Antiviral Therapy|June 22, 2018
Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adultsThomas N Kakuda, Jeysen Yogaratnam, Jennifer Rito, et al.
Hepatology (Baltimore, Md.)|August 3, 2018
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without CirrhosisEdward J Gane, Catherine A Stedman, Christian Schwabe, et al.
Hepatology (Baltimore, Md.)|June 28, 2003
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis BChristopher E Westland, Huiling Yang, William E Delaney, et al.
Hepatology (Baltimore, Md.)|July 27, 2002
Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeksHuiling Yang, Christopher E Westland, William E Delaney, et al.
Blood|December 21, 2011
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myelomaJeffrey A Zonder, Ann F Mohrbacher, Seema Singhal, et al.
Gastroenterology|July 10, 2003
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1Chris Westland, William Delaney, Huiling Yang, et al.
Advances in Therapy|March 6, 2020
Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy SubjectsJoris Vandenbossche, Wolfgang Jessner, Maarten van den Boer, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Journal of Environmental Management|October 29, 2013
Evaluating Ireland's IBIA as an approach to improving the quality and effectiveness of biodiversity impact assessmentAinhoa González, Tamara Hochstrasser, John Fry, et al.
Journal of Human Kinetics|July 18, 2017
A Comparison of GPS Workload Demands in Match Play and Small-Sided Games by the Positional Role in Youth SoccerMathew Beenham, David J Barron, John Fry, et al.
Antiviral Therapy|November 21, 2025
A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participantsEd Gane, Christian Schwabe, Min Wu, et al.
Antiviral Therapy|June 22, 2018
Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adultsThomas N Kakuda, Jeysen Yogaratnam, Jennifer Rito, et al.
Hepatology (Baltimore, Md.)|August 3, 2018
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without CirrhosisEdward J Gane, Catherine A Stedman, Christian Schwabe, et al.
Hepatology (Baltimore, Md.)|June 28, 2003
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis BChristopher E Westland, Huiling Yang, William E Delaney, et al.
Hepatology (Baltimore, Md.)|July 27, 2002
Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeksHuiling Yang, Christopher E Westland, William E Delaney, et al.
Blood|December 21, 2011
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myelomaJeffrey A Zonder, Ann F Mohrbacher, Seema Singhal, et al.
Gastroenterology|July 10, 2003
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1Chris Westland, William Delaney, Huiling Yang, et al.
Advances in Therapy|March 6, 2020
Correction to: Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy SubjectsJoris Vandenbossche, Wolfgang Jessner, Maarten van den Boer, et al.
Pageof 4